Ozelle to Show O-Cyte 1 AI-Assisted Hematology Analyzer at MEDICA 2026 in Düsseldorf

Ozelle will spotlight O-Cyte 1, an automated hematology analyzer combining CBC testing with cell imaging and AI-assisted classification, at MEDICA 2026 in Düsseldorf from November 16 to 19. The company announced the showcase on October 28, Newswire reported.

How O-Cyte 1 Handles Blood Morphology

Ozelle's O-Cyte 1 performs CBC testing with 7-part white blood cell differentiation, integrating high-resolution cell imaging and AI-assisted classification in the same analyzer. Cell images are linked to numerical results so laboratory professionals can examine visual evidence when needed.

The analyzer is built for changing workloads and routine service needs. A standalone unit delivers up to 60 tests per hour, while a six-unit cascade reaches up to 360 tests per hour. An integrated reagent kit and key fluid-contact components housed in consumables are designed to simplify reagent handling and reduce routine maintenance, and built-in self-checks and replaceable modules support fault identification and servicing.

Ozelle said the design reflects its vision for the fourth generation of hematology analysis: "making morphology intelligence more consistent, reviewable and scalable across routine hematology workflows." The company said the International Council for Standardization in Haematology approved a new digital morphology standardization project at its October 14-15 General Assembly, an initiative it said highlights verification, reproducibility and quality assurance in digital morphology.

For IVD distributors, Ozelle said scalable configurations help serve laboratories with different testing volumes and provide a path for future capacity expansion. Simplified reagent management and modular design can also ease ongoing technical support and after-sales service.

Other Ozelle Systems at the Düsseldorf Booth

At MEDICA, Ozelle will also feature the EHBT-75, which combines 7-diff hematology with cell imaging and morphology analysis, and the EHBT-50, which integrates hematology, immunoassay and dry biochemistry in a compact platform. Visitors can also explore Open Dx, Ozelle's AI Workbench for AI-assisted report review and result sharing. The company will meet visitors in Hall 1, Booth D63 at Messe Düsseldorf to discuss distribution opportunities.

O-Cyte 1's Earlier Debut and Company Scale

According to akta.pro company records, Ozelle gave O-Cyte 1 its global debut at ADLM 2026 in Anaheim, California, in June 2026, with the same throughput figures of up to 60 tests per hour standalone and 360 tests per hour via cascade expansion. The same records list more than 50,000 global installations, more than 50 million cell images generated daily from the installed base and more than 100 billion cell data points accumulated in clinical workflows.

Ozelle's Path to MEDICA 2026

Ozelle announced in June 2026 that it would debut O-Cyte 1 at ADLM 2026 in Anaheim, California, describing the product as its latest milestone in AI-powered hematology analysis using its AI × CBM technology, PR Newswire reported. In July 2026, Aijourn reported that Ozelle had launched O-Cyte 1 at ADLM 2026, marking its entry into AI-powered hematology.

Ozelle's company website describes the company as founded in Silicon Valley in 2014 and developing AI-powered hematology and integrated diagnostic systems for human and veterinary care.